Yilmaz Mahshid becomes CEO of Medivir
Yilmaz Mahshid is to join the Swedish biotech company Medivir AB as chief executive officer, replacing Uli Hacksell, who will stay on the board of directors.
Sweden
Yilmaz Mahshid is to join the Swedish biotech company Medivir AB as chief executive officer, replacing Uli Hacksell, who will stay on the board of directors.
Sweden
Ravi Rao has joined Sobi (Swedish Orphan Biovitrum AB) as its new head of research and development, replacing Milan Zdravkovic who is leaving the company.
Sweden
Sven Rohmann, a medical doctor and biotech executive, has been appointed chief executive of Immunicum AB to lead clinical development of the Swedish company’s cell-based therapy for cancer.
Sweden
Neil Bell, an expert in clinical development, has joined Avacta Life Sciences Ltd as chief development officer to manage human studies of the company’s lead drug, a pro-doxorubicin compound.
United Kingdom
Erich Schlick, a venture capitalist and industrialist, has been appointed chair of the board of directors of Switzerland-based NBE-Therapeutics GmbH which is developing antibody-drug conjugates. He is currently a general partner and managing director at Wellington Partners in Munich.
Switzerland
Nordic Nanovector ASA has appointed Christine Wilkinson Blanc as chief medical officer to help it advance its portfolio of targeted cancer therapies.
Norway
Peter Selin, an experienced business development executive, has been appointed chief business officer at Oasmia Pharmaceutical AB, a Swedish specialty pharma company.
Sweden
Thomas Burt, a venture capitalist, has become a non-executive director at Redx Pharma Plc, representing the Sofinnova Crossover Fund, a recent investor. Mr Burt has been a partner in the fund since its inception in 2017.
United Kingdom
The France-based vaccine company Valneva SE has appointed Juan Carlos Jaramillo as chief medical officer, effective 1 October, to lead the company’s portfolio of preventive treatments against Lyme disease, chikungunya and SARS-COV-2.
France
Paul Higham, an experienced manager, has joined Valo Therapeutics Ltd as chief executive to lead the company through a new financing round and help take its first oncolytic virus compound into the clinic.
United Kingdom
© 2021 Evernow Publishing Ltd. Powered by Drupal.